Why the study?
The study investigated the association between fenofibrate use and heart failure outcomes in patients with Type 2 diabetes.
Does the addition of fenofibrate to statin therapy reduce hospitalization for heart failure or cardiovascular death in patients with Type 2 diabetes?
Population
Patients with T2D (≥30 years) receiving statin therapy in South Korea (n = 11 722 per group)
Comparison
Statin plus fenofibrate vs statin only
Design
Nationwide propensity-matched cohort study
Follow-up
Median of 50.4 months
Key result
The addition of fenofibrate to statin therapy in patients with Type 2 diabetes was associated with a lower risk of hospitalization for heart failure (HR 0.80; 95% CI 0.65-0.98).
Authors
Loading...
May support adjunctive fenofibrate in statin-treated T2D; leaves open confirmation in randomized trials.
Cohort (n=23,444)
Yes
Does the addition of fenofibrate to statin therapy reduce hospitalization for heart failure or cardiovascular death in patients with Type 2 diabetes?
Hazard Ratio: 0.8 (95% CI 0.65–0.98)
Absolute Event Rate: 3.44% vs 4.13%
In patients with Type 2 diabetes on statin therapy, the addition of fenofibrate is associated with a significantly lower risk of incident heart failure hospitalization and cardiovascular death.
Kim et al. (2025) conducted a cohort in Type 2 diabetes (n=23,444). Fenofibrate vs. Statin only was evaluated on Hospitalization for heart failure (HHF) (HR 0.80, 95% CI 0.65-0.98). The addition of fenofibrate to statin therapy in patients with Type 2 diabetes was associated with a lower risk of hospitalization for heart failure (HR 0.80; 95% CI 0.65-0.98).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: